Navigation Links
Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Naviscan, Inc. announced that it has entered into an exclusive licensing agreement with Neoprobe Corporation (NYSE Amex: NEOP) as a partner to further develop its patented imaging technology.  While most of the patents in Naviscan's extensive intellectual property portfolio were designed to enable innovation in organ-specific molecular imaging, several more recently-allowed patents were devised to further broaden the company's product base. One such patent, now licensed to Neoprobe, enables a novel gamma ray detector, or a gamma probe, to translate gamma emission data into a 3-dimensional representation of a gamma-emitting source, such as a malignant lesion or tumor.

Maintaining its lead in the field of Molecular Breast Imaging, Naviscan continues to devote its resources to commercializing its current PET scanner and biopsy-guidance accessories, both optimized for breast imaging, and expanding its platform to other applications (e.g. head, neck, extremities, etc.).  Partnering with Neoprobe, a leader in 3-D gamma imaging, allows Naviscan technology to be developed in cancer surgical applications.

"Our expanding patent portfolio continues to strengthen our clinically-relevant, technology leadership while creating opportunities to build strategic partnerships, monetize our intellectual properties and, in turn, increase the company's valuation.  Toward that end, this licensing agreement provides an opportunity for Naviscan to work with a proven development partner in the gamma detection instrumentation space with a strong record of commercialization success," said Paul Mirabella, Chairman and CEO of Naviscan, Inc. "Neoprobe's competencies and resources are well-suited to build upon our 3-dimensional molecular imaging technology and realize its full value."  

"Our agreement with Naviscan provides an opportunity to augment our strategic positioning in the gamma detection space in partnership with a proven leader in the cancer imaging space.  We believe the 3-dimensional gamma imaging technology from Naviscan is a natural extension of our current line of gamma detection devices and enhances the opportunities in this technology category, while opening new opportunities to expand our product platform and advance pipeline development," said Mark Pykett, Executive Vice President and Chief Development Officer of Neoprobe. "The Naviscan platform allows Neoprobe to explore gamma detection products that could lead to new indications for Lymphoseek® and RIGScanTM CR.  Additionally, Naviscan 's 3-dimensional gamma camera technology could be optimized for surgical applications that may lead to improved diagnosis and care of patients with cancer and potentially patients with other diseases."

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit

About Neoprobe

Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit.  Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons.  In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR.  Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT.  Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. West Appoints Two Directors and Announces Second Quarter 2011 Dividend
2. Video from Lundbeck available on Lundbeck Announces 2010 Results: Meet all Financial Expectations
3. Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System
4. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
5. OrthoAccel Technologies, Inc. Announces New Scientific Advisor
6. Regeneron Announces March 2011 Investor Conference Presentations
7. Generex Announces New Treatment IND Site for the USFDA Expanded Access Treatment IND Program for Generex Oral-lyn™ in the United States
8. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
9. Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
10. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
11. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
Post Your Comments:
(Date:10/13/2015)... MUNICH , October 13, 2015 ... --> World Thrombosis Day Interactive Infographic   ... World Thrombosis Day  to promote vital ... and signs and symptoms. Thrombosis is the formation ... (venous thrombosis) - resulting in venous thromboembolism (VTE) ...
(Date:10/13/2015)... PARK, Calif. , Oct. 13, 2015 /PRNewswire/ ... an agreement with the UK-based Cell Therapy Catapult ... for AST-VAC2, Asterias, allogeneic dendritic cell immunotherapy. Under ... and scale manufacturing processes for AST-VAC2 to support ... --> --> ...
(Date:10/12/2015)... -- Given the intricacy of the anatomy and ... an ophthalmic drug effectively to a specific ocular site. Several ... delivery. These include dilution of a drug by tears, clearance ... drug permeation issues with respect to the cornea, sclera and ... is lost due to the aforementioned barriers. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... "My friend's ... his fists into his infected cheeks," said an inventor from Platteville, Colo. "I came ... skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... ... According to an article published October 5th by the American ... weight with a bariatric procedure are much less likely to develop endometrial cancer, which ... from 40 to 50 percent of all endometrial cancer cases are caused by obesity, ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... provider of IBM software products, introduced a new company, RightSensor™ LLC, an Internet ... data communications capability. RightSensor™ provides a fully-managed approach for customers requiring sensor ...
Breaking Medicine News(10 mins):